ST Xiangxue: Announcement of Resolutions of the 34th Meeting of the Ninth Board of Directors
Securities code: 300147 Securities abbreviation: ST Xiangxue Announcement number: 2026-006
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 34th Meeting of the Ninth Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
The 34th meeting of the ninth board of directors of Guangzhou Xiangxue Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on March 30, 2026 in the conference room of the company's headquarters through on-site communication and communication. The meeting notice was delivered to all directors by email, phone, etc. on March 27, 2026. Six directors were supposed to attend the meeting, but six directors actually attended. Independent directors Mr. Wu Jie, Mr. Zhou Qingquan, and Ms. Tao Jianhong attended by communication. There was no delegation to attend. The company's senior management and other relevant personnel attended the meeting. The meeting was chaired by Chairman Wang Yonghui. The convening, discussion methods and voting procedures of this meeting complied with the provisions of the "Company Law of the People's Republic of China" and the "Articles of Association" on the convening of the board of directors. The following resolutions were adopted by voting:
1. The "Proposal on Application for Loan Renewal" was reviewed and approved
The meeting agreed that the company would apply to the Huangpu Branch of Guangzhou Rural Commercial Bank Co., Ltd. for a loan extension of RMB 550 million. The extension would not exceed two years and would be used for the company's operations and production development. The original mortgage and other guarantees for the loan would be renewed accordingly. The meeting agreed to authorize the chairman of the company or his designated authorized representative to sign relevant contracts, agreements and other legal documents (including but not limited to loans, guarantees, mortgages, etc.) and handle related loan renewal matters.
For details, please refer to the "Announcement on Application for Loan Renewal" disclosed by the company on cninfo.com.
Voting results: 6 votes in favor, 0 votes against, and 0 abstentions.
2. The "Proposal on the Company's Transfer of Equity Interests in Subsidiaries" was reviewed and approved
The meeting agreed that the company would transfer 100% of the equity of its wholly-owned subsidiary Guangdong Jiuji Biotechnology Co., Ltd. to the company's wholly-owned subsidiary Guangzhou Xiangxue High-tech Investment Co., Ltd. at book value free of charge, and signed a "Share Transfer Contract". The meeting authorized the chairman of the company to sign relevant documents for this transaction.
For details, please refer to the "Announcement on the Company's Transfer of Equity Interests in Subsidiaries" published on the GEM information disclosure website designated by the China Securities Regulatory Commission.
This proposal has been reviewed and approved by the company's audit committee.
Voting results: 6 votes in favor, 0 votes against, and 0 abstentions.
Announcement is hereby made.
Board of Directors of Guangzhou Xiangxue Pharmaceutical Co., Ltd.
March 30, 2026